NASDAQ NMS - GLOBAL MARKET · GDRX
-0.61% · -$0.0200 · Vol 548.5K
Market closed · last close 4:00 PM ET · price as of 16:01:30 ET
GoodRx Holdings Inc

GoodRx Holdings Inc

Health Care
$3.25
Card
Relationship Map

Follow $GDRX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $GDRX by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
GDRX
GoodRx Holdings Inc
Wed Oct 7 · market closed · Markets closed · resumes Thu 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

60/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: MEDIUM · 5 of 6 factors measured · Wed Oct 7 · market closed · Markets closed · resumes Thu 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GDRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GDRX catalysts
About GoodRx Holdings Inc
SERVICES-COMPUTER PROCESSING & DATA PREPARATION
Listed since
2020
Employees
697
Country
US

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.24
Day high
$3.30
Day low
$3.23
Previous close
$3.27
52W high
$4.64
-29.96% from high
52W low
$1.87
50% of range
Market cap
$1.1B
P/E
68.02×
EPS
$0.0469
Beta
0.85
Shares out
341.1M
Volume
548.5K
0.55× rel vol
Avg volume
1M
VWAP
$3.27
Price history computed in-house
1W
-0.61%
1M
-7.67%
3M
+10.17%
1Y
-25.97%
YTD
+19.93%
SMA 50 $3.44 · below
SMA 200 $2.76 · above
52W position 50%

GDRX overview

Loading financial statements
Loading GDRX Form 4 filings
Public disclosures

Congress activity in GDRX

1 filers · 1 buys · 0 sells (0 labeled S (partial)) · Mar 25, 2021 to Mar 25, 2021 · House 1 / Senate 0

All available history · Latest 1 of 1 lines · Read 2026-10-08T00:09:56.418Z

Federal contracts

GDRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GDRX in this window.
Lobbying spend

GDRX lobbying filings, year to date.

Registered lobbying filings matched to GoodRx Holdings Inc.

$1.2M
Refresh interval: 12hSource: LDA disclosure filings
Health IssuesHealth Issues Consumer Issues/Safety/ProductsConsumer Issues/Safety/Products Health Issues
Filing
$380.0K
GOODRX INC.

GOODRX, INC.

Jul 20, 2026
Filing
$370.0K
GOODRX INC.

GOODRX, INC.

Apr 20, 2026
Filing
$300.0K
GOODRX INC.

GOODRX, INC.

Jan 20, 2026
Loading news for GDRX
Analyst ratings
Sovereign unlock shows live analyst consensus for GDRX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.